Biogen (IDP) – aksjekurser og nyheter

Symboler Symboler	Pris	Endring	Endring (%)	Trend	Forrige pris ved stengetid	Åpne	Høy	Lav	Volum	Markedsverdi
SIXB Materials SIXB Materials	SIXB −0,82%	1 083,83	−8,97	−0,82%	—	1 092,80	1 093,68	1 094,85	1 083,04	—	—
SIXC Communications SIXC Communications	SIXC −0,33%	602,76	−1,98	−0,33%	—	604,74	604,74	605,10	601,66	—	—
SIXE Energy SIXE Energy	SIXE +1,41%	1 231,94	+17,14	+1,41%	—	1 214,80	1 220,81	1 233,62	1 220,81	—	—
SIXI Industrials SIXI Industrials	SIXI −0,91%	1 708,86	−15,71	−0,91%	—	1 724,57	1 727,02	1 732,30	1 708,36	—	—
SIXM Financials SIXM Financials	SIXM −0,07%	638,96	−0,47	−0,07%	—	639,43	641,58	644,53	638,07	—	—
SIXR Staples SIXR Staples	SIXR −0,49%	835,07	−4,08	−0,49%	—	839,15	836,90	838,79	832,89	—	—
SIXRE Real estate SIXRE Real estate	SIXRE −0,81%	213,90	−1,75	−0,81%	—	215,62	215,62	216,21	213,85	—	—
SIXT Technology SIXT Technology	SIXT +0,53%	3 196,31	+16,79	+0,53%	—	3 179,52	3 191,50	3 205,09	3 178,28	—	—
SIXU Utilities SIXU Utilities	SIXU −0,78%	929,58	−7,33	−0,78%	—	936,91	935,42	937,17	929,54	—	—
SIXV Health care SIXV Health care	SIXV −0,81%	1 440,95	−11,82	−0,81%	—	1 452,77	1 445,93	1 446,24	1 434,91	—	—
SIXY Discretionary SIXY Discretionary	SIXY −0,17%	2 361,12	−4,06	−0,17%	—	2 365,18	2 353,64	2 368,10	2 348,51	—	—

IDP:FRA

Biogen

162,52 €

+4,60%

(+7,14) 1 D

29. apr., 15:44:26 GMT+2 · EUR

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for IDP …

Åpne

156,30 €

Høy

162,52 €

Lav

156,30 €

Markedsverdi

27,88 mrd.

Snittvolum

23,00

Volum

0,00

52 u høy

169,30 €

52 u lav

102,00 €

Antall ansatte

Relaterte aksjer

Bitterroot Resources Ltd

0,040 CAD

−27,27%

CMF

iShares California Muni Bond ETF

57,26 USD

−0,28%

Nyhetssaker

Fra kilder på nettet

BioSpace

for 51 minutter siden

With growth curve trending up, Biogen looks for early-stage assets for ‘next generation’

GuruFocus

for 54 minutter siden

Biogen (BIIB) Lowers 2026 Earnings Guidance Despite Q1 Sales Gro

The Pharma Letter

for 1 time siden

Biogen posts Q1 beat as Alzheimer's drug drives growth

Investing.com

for 2 timer siden

Earnings call transcript: Biogen Q1 2026 beats expectations with strong EPS and revenue growth

Profil

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia

Om Biogen

Administrerende direktørChristopher A. Viehbacher

Ansatte7,5k

Grunnlagt1978

HovedkontorCambridge, Massachusetts, USA

Sektor-

Nettstedbiogen.com

Alle verdier i USD	mars 2025	juni 2025	sep. 2025	des. 2025
Inntekt	2,43 mrd.	2,65 mrd.	2,53 mrd.	2,28 mrd.
Varekostnad	577,90 mill.	946,20 mill.	508,60 mill.	443,40 mill.
Direkte driftskostnader	577,90 mill.	946,20 mill.	508,60 mill.	443,40 mill.
Utgifter til forskning og utvikling	426,70 mill.	-	431,80 mill.	501,00 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	574,60 mill.	581,30 mill.	592,80 mill.	685,20 mill.
Driftskostnader	1,17 mrd.	783,70 mill.	1,25 mrd.	1,39 mrd.
Totale driftskostnader	1,75 mrd.	1,73 mrd.	1,76 mrd.	1,83 mrd.
Driftsinntekter	681,90 mill.	915,60 mill.	778,60 mill.	447,70 mill.
Andre ikke-operasjonelle inntekter	−500,00k	−3,30 mill.	15,80 mill.	17,40 mill.
EBT inkludert uvanlige elementer	311,20 mill.	744,00 mill.	557,30 mill.	−56,00 mill.
EBT uten uvanlige elementer	649,10 mill.	861,60 mill.	748,30 mill.	423,10 mill.
Kostnad for inntektsskatt	70,70 mill.	109,20 mill.	90,80 mill.	−7,10 mill.
Faktisk avgiftssats	22,72 %	14,68 %	16,29 %	12,68 %
Andre driftskostnader	58,10 mill.	75,00 mill.	87,20 mill.	69,90 mill.
Nettoinntekt	240,50 mill.	634,80 mill.	466,50 mill.	−48,90 mill.
Netto fortjenestemargin	9,89 %	24,00 %	18,40 %	−2,15 %
Resultat per aksje	3,02	5,47	4,81	1,99
Rente- og investeringsinntekter	23,90 mill.	32,30 mill.	31,60 mill.	37,20 mill.
Rentekostnader	−60,00 mill.	−72,60 mill.	−67,40 mill.	−67,50 mill.
Netto rentekostnader	−36,10 mill.	−40,30 mill.	−35,80 mill.	−30,30 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	865,10 mill.	1,11 mrd.	980,80 mill.	647,90 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning